Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse

Mantle cell lymphoma (MCL) is an aggressive, difficult to treat subtype of lymphoma, resulting in relapses and poor outcomes. Novel agents such as Bruton tyrosine kinase (BTK) inhibitors have been studied in the treatment of relapsed/refractory (R/R) MCL. BTK inhibitor ibrutinib, in particular, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Timothy S., Burkart, Madelyn, Behdad, Amir, Savas, Hatice, Karmali, Reem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106524/
https://www.ncbi.nlm.nih.gov/pubmed/35571529
http://dx.doi.org/10.1155/2022/1930546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106524/
https://www.ncbi.nlm.nih.gov/pubmed/35571529
http://dx.doi.org/10.1155/2022/1930546

Ejemplares similares